Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting, 55264-55265 [2020-19678]

Download as PDF jbell on DSKJLSW7X2PROD with NOTICES 55264 Federal Register / Vol. 85, No. 173 / Friday, September 4, 2020 / Notices through a maneuver agreement granted by the Territory of Hawai1i. In 1964, the State granted a 65-year lease of approximately 23,000 acres of land to the Army for military purposes. The lease expires on August 16, 2029. The 23,000 acres of State-owned land contain utilities, critical infrastructure, maneuver land, and key training facilities, some of which are not available elsewhere in Hawai1i. The land also provides access to approximately 110,000 acres of adjacent U.S. Government-owned land at PTA. PTA encompasses approximately 132,000 acres of land used for training military personnel for combat. It is the only U.S. training area in the Pacific region where training units can complete all mission essential tasks, and the only U.S. training facility in the Pacific region that can accommodate larger than company-sized units for livefire and maneuver exercises. The U.S. Army Hawaii (USARHAW) and other U.S. military units that train at PTA include the 25th Infantry Division, U.S. Marine Corps, U.S. Navy, U.S. Air Force, Hawaii National Guard, and U.S. Army Reserve. The Army’s retention of State-owned land within PTA is needed to enable USARHAW to continue to conduct military training to meet its current and future training requirements. Retention of State-owned land is needed to allow access between major parcels of U.S. Government-owned land at PTA, retain substantial Army infrastructure investments, allow for future facility and infrastructure modernization, preserve limited maneuver area, provide austere environment training, and maximize use of the impact area in support of USARHAW-coordinated training. To understand the environmental consequences of the decision to be made, the EIS will evaluate the potential direct, indirect, and cumulative impacts of a range of reasonable alternatives that meet the purpose of, and need for, the Proposed Action. Alternatives to be considered, including the no action alternative, are (1) Full Retention, (2) Modified Retention, and (3) Minimum Retention and Access. Other reasonable alternatives raised during the scoping process and capable of meeting the project purpose and need will be considered for evaluation in the EIS. Native Hawaiian organizations; Federal, state, and local agencies; and the public are invited to be involved in the scoping process for the preparation of this EIS by participating in a scoping meeting and/or submitting written comments. The scoping process will help identify potential environmental VerDate Sep<11>2014 16:42 Sep 03, 2020 Jkt 250001 impacts and key issues of concern to be analyzed in the EIS. Written comments must be sent within 40 days of publication of the Notice of Intent in the Federal Register. In response to the coronavirus (COVID–19) pandemic in the United States and the Center for Disease Control’s recommendations for social distancing and avoiding large public gatherings, the Army will not hold public scoping meetings for this action. In lieu of the public scoping meetings, the Army will use other alternative means to enable public participation such as virtual meetings using online meeting/collaboration tools, teleconference, social media, or email, as appropriate. An EIS Scoping Virtual Open House and two in-person scoping comment stations will be held on Wednesday, September 23, 2020 from 4–9 p.m. During the EIS Scoping Virtual Open House, video presentations can be viewed online at https://home.army.mil/hawaii/ index.php/PTAEIS and oral and written comments will be accepted. Oral comments will be accepted via phone by calling (808) 300–0220. The two inperson scoping comment stations will also be open to the public to accept oral comments via phone and written comments: One in-person scoping comment station will be in Hilo, and the other will be in Waimea, both on the island of Hawai1i; individuals making comments will maintain recommended social distance. Notification of the EIS Scoping Virtual Open House and inperson scoping comment stations date and time will also be published and announced in local news media outlets and on the EIS website. For those who do not have ready access to a computer or the internet, the scoping materials posted to the EIS website will be made available upon request by mail. Inquiries and requests for scoping materials may be made to Michael Donnelly, PTA Public Affairs Officer at (808) 969–2411 or by email at michael.o.donnelly.civ@mail.mil. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2020–19620 Filed 9–3–20; 8:45 am] BILLING CODE 5061–AP–P DEPARTMENT OF DEFENSE Office of the Secretary Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting Under Secretary of Defense for Personnel and Readiness, Department of Defense (DoD). AGENCY: PO 00000 Frm 00013 Fmt 4703 Sfmt 4703 Notice of Federal Advisory Committee meeting. ACTION: The DoD is publishing this notice to announce the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel will take place. DATES: Open to the public Wednesday, September 23, 2020, from 12:00 p.m. to 6:00 p.m. (Eastern Daylight Time). ADDRESSES: The open meeting will be held online. The phone number for remote access is CONUS: 888–469– 2037; OCONUS: 1–517–308–9287; PARTICIPANT CODE: 8227323. These numbers and the dial-in instructions will also be posted on the Uniform Formulary Beneficiary Advisory Panel website at: https://www.health.mil/ About-MHS/OASDHA/Defense-HealthAgency/Operations/Pharmacy-Division/ Beneficiary-Advisory-Panel. FOR FURTHER INFORMATION CONTACT: Colonel Paul J. Hoerner, USAF, 703– 681–2890 (Voice), dha.ncr.j6.mbx.baprequests@mail.mil (Email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042–5101. Website: https:// www.health.mil/About-MHS/OASDHA/ Defense-Health-Agency/Operations/ Pharmacy-Division/BeneficiaryAdvisory-Panel. The most up-to-date changes to the meeting agenda can be found on the website. SUPPLEMENTARY INFORMATION: This meeting is being held under the provisions of the Federal Advisory Committee Act (FACA) (5 U.S.C., Appendix), the Government in the Sunshine Act (5 U.S.C. 552b), and 41 CFR 102–3.140 and 102–3.150. The Panel will review and comment on recommendations made to the Director, Defense Health Agency, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary. Purpose of the Meeting: The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel will take place. SUMMARY: Agenda 1. Sign-In 2. Welcome and Opening Remarks 3. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item) a. Psoriasis Agents—NA b. Sleep Disorders—Wakefulness Promoting Agents c. White Blood Cell Stimulants— Filgrastims d. White Blood Cell Stimulants— Pegfilgrastims E:\FR\FM\04SEN1.SGM 04SEN1 Federal Register / Vol. 85, No. 173 / Friday, September 4, 2020 / Notices 4. Newly-Approved Drugs Review 5. Pertinent Utilization Management Issues 6. Panel Discussions and Vote Meeting Accessibility: Pursuant to 5 U.S.C. 552b, and 41 CFR 102–3.140 through 102–3.165, and the subject to availability of phone lines, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people dialing in. There will be 220 lines total: 200 domestic and 20 international, including leader lines. Written Statements: Pursuant to 41 CFR 102–3.10, and section 10(a)(3) of FACA, interested persons or organizations may submit written statements to the Uniform Formulary Beneficiary Advisory Panel about its mission and/or the agenda to be addressed in this public meeting. Written statements should be submitted to the Uniform Formulary Beneficiary Advisory Panel’s Designated Federal Officer (DFO). The DFO’s contact information can be found in the FOR FURTHER INFORMATION CONTACT section of this notice. Written comments or statements must be received by the Uniform Formulary Beneficiary Advisory Panel’s DFO at least five (5) business days prior to the meeting so they may be made available to the Uniform Formulary Beneficiary Advisory Panel for its consideration prior to the meeting. The DFO will review all submitted written statements and provide copies to all Uniform Formulary Beneficiary Advisory Panel members. Dated: September 1, 2020. Aaron T. Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2020–19678 Filed 9–3–20; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF DEFENSE Department of the Navy Meeting of the U.S. Naval Academy Board of Visitors Department of the Navy, U.S. Department of Defense (DoD). ACTION: Notice of Partially Closed Meeting. AGENCY: The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the U.S. Naval Academy Board of Visitors, hereafter ‘‘Board,’’ will take place. jbell on DSKJLSW7X2PROD with NOTICES SUMMARY: Open to the public, September 14, 2020, from 10 a.m. to 12 p.m. Closed DATES: VerDate Sep<11>2014 16:42 Sep 03, 2020 Jkt 250001 to the public, September 14, 2020, from 12 p.m. to 1 p.m. ADDRESSES: This a virtual meeting that will be broadcasted live from the United States Naval Academy in Annapolis, MD. Escort is not required. FOR FURTHER INFORMATION CONTACT: Major Raphael Thalakottur, USMC, Executive Secretary to the Board of Visitors, Office of the Superintendent, U.S. Naval Academy, Annapolis, MD 21402–5000, 410–293–1503, thalakot@ usna.edu, or visit https:// www.usna.edu/PAO/Superintendent/ bov.php. This meeting is being held under the provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 U.S.C., Appendix, as amended), the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended), the General Services Administration’s (GSA) Federal Advisory Committee Management Final Rule (41 CFR part 102–3). Purpose of Meeting: The U.S. Naval Academy Board of Visitors will meet to make such inquiry, as the Board deems necessary, into the state of morale and discipline, the curriculum, instruction, physical equipment, fiscal affairs, and academic methods of the Naval Academy. SUPPLEMENTARY INFORMATION: Agenda Proposed meeting agenda for September 14, 2020. 0930–1000 Assemble/Members log on (Broadcasted to Public) 1000 Call to Order (Broadcasted to Public) 1000–1155 Business Session (Broadcasted to Public) 1155–1200 Break (Broadcasted to Public) 1200–1300 Executive Session (Closed to Public) Current details on the board of visitors may be found at https:// www.usna.edu/PAO/Superintendent/ bov.php. The executive session of the meeting from 12:00 p.m. to 1:00 p.m. on September 14, 2020, will consist of discussions of new and pending administrative or minor disciplinary infractions and non-judicial punishments involving midshipmen attending the Naval Academy to include but not limited to, individual honor or conduct violations within the Brigade, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. For this reason, the executive session of this meeting will be closed to the public, as the discussion of such information PO 00000 Frm 00014 Fmt 4703 Sfmt 4703 55265 cannot be adequately segregated from other topics, which precludes opening the executive session of this meeting to the public. Accordingly, the Secretary of the Navy, in consultation with the Department of the Navy General Counsel, has determined in writing that the meeting shall be partially closed to the public because the discussions during the executive session from 12 p.m. to 1 p.m. will be concerned with matters protected under sections 552b(c)(5), (6), and (7) of title 5, United States Code. Authority: 5 U.S.C. 552b. Meeting Accessibility: Pursuant to FACA and 41 CFR 102–3.140, this meeting is virtually open to the public. This meeting will be broadcasted live from the United States Naval Academy to include audio and video. The broadcast will be close captioned for the duration of the public portion of the meeting. The link to view the meeting will be posted at https://www.usna.edu/ PAO/Superintendent/bov.php fortyeight hours prior to the meeting. Due to expected health directives in light of COVID–19, the public cannot be accommodated to attend the meeting in person. Written Statements: Per Section 10(a)(3) of the FACA and 41 CFR 102– 3.105(j) and 102–3.140, interested persons may submit a written statement for consideration at any time, but should be received by the Designated Federal Officer at least 10 business days prior to the meeting date so that the comments may be made available to the Board for their consideration prior to the meeting. Written statements should be submitted via mail to 121 Blake Rd., Annapolis MD 21402. Please note that since the Board operates under the provisions of the FACA, as amended, all submitted comments and public presentations will be treated as public documents and will be made available for public inspection, including, but not limited to, being posted on the board website. Due to circumstances beyond the control of the DoD and the Designated Federal Officer, the Board of Visitors, United States Naval Academy was unable to provide public notification required by 41 CFR 102– 3.150(a) concerning its meeting of September 14, 2020. Accordingly, the Advisory Committee Management Officer for the DoD, pursuant to 41 CFR 102–3.150(b) waives the 15-calendar day notification requirement. E:\FR\FM\04SEN1.SGM 04SEN1

Agencies

[Federal Register Volume 85, Number 173 (Friday, September 4, 2020)]
[Notices]
[Pages 55264-55265]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-19678]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Under Secretary of Defense for Personnel and Readiness, 
Department of Defense (DoD).

ACTION: Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The DoD is publishing this notice to announce the following 
Federal Advisory Committee meeting of the Uniform Formulary Beneficiary 
Advisory Panel will take place.

DATES: Open to the public Wednesday, September 23, 2020, from 12:00 
p.m. to 6:00 p.m. (Eastern Daylight Time).

ADDRESSES: The open meeting will be held online. The phone number for 
remote access is CONUS: 888-469-2037; OCONUS: 1-517-308-9287; 
PARTICIPANT CODE: 8227323. These numbers and the dial-in instructions 
will also be posted on the Uniform Formulary Beneficiary Advisory Panel 
website at: https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel.

FOR FURTHER INFORMATION CONTACT: Colonel Paul J. Hoerner, USAF, 703-
681-2890 (Voice), [email protected] (Email). Mailing 
address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 
22042-5101. Website: https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel. 
The most up-to-date changes to the meeting agenda can be found on the 
website.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act (FACA) (5 U.S.C., 
Appendix), the Government in the Sunshine Act (5 U.S.C. 552b), and 41 
CFR 102-3.140 and 102-3.150.
    The Panel will review and comment on recommendations made to the 
Director, Defense Health Agency, by the Pharmacy and Therapeutics 
Committee, regarding the Uniform Formulary.
    Purpose of the Meeting: The DoD is publishing this notice to 
announce that the following Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel will take place.

Agenda

1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Psoriasis Agents--NA
    b. Sleep Disorders--Wakefulness Promoting Agents
    c. White Blood Cell Stimulants--Filgrastims
    d. White Blood Cell Stimulants--Pegfilgrastims

[[Page 55265]]

4. Newly-Approved Drugs Review
5. Pertinent Utilization Management Issues
6. Panel Discussions and Vote
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, and 41 CFR 102-
3.140 through 102-3.165, and the subject to availability of phone 
lines, this meeting is open to the public. Seating is limited and will 
be provided only to the first 220 people dialing in. There will be 220 
lines total: 200 domestic and 20 international, including leader lines.
    Written Statements: Pursuant to 41 CFR 102-3.10, and section 
10(a)(3) of FACA, interested persons or organizations may submit 
written statements to the Uniform Formulary Beneficiary Advisory Panel 
about its mission and/or the agenda to be addressed in this public 
meeting. Written statements should be submitted to the Uniform 
Formulary Beneficiary Advisory Panel's Designated Federal Officer 
(DFO). The DFO's contact information can be found in the FOR FURTHER 
INFORMATION CONTACT section of this notice. Written comments or 
statements must be received by the Uniform Formulary Beneficiary 
Advisory Panel's DFO at least five (5) business days prior to the 
meeting so they may be made available to the Uniform Formulary 
Beneficiary Advisory Panel for its consideration prior to the meeting. 
The DFO will review all submitted written statements and provide copies 
to all Uniform Formulary Beneficiary Advisory Panel members.

    Dated: September 1, 2020.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2020-19678 Filed 9-3-20; 8:45 am]
BILLING CODE 5001-06-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.